The Paid-To-Hold Play On ISRG Stock: A 12% Annualized Income

Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.

Intuitive Surgical (ISRG) has been a frustrating stock to own lately, trading about 32% below its 52-week high and lagging the broader market. For shareholders sitting on this surgical robotics pioneer, that kind of sideways action raises a question: what if you could get paid a meaningful income right now, an upfront payment you keep regardless of what the stock does next? That’s the logic behind the specific options trade laid out below.

12% annualized income on ISRG shares you already own, with 15% of upside room, by selling a covered call.

• You own (or buy) 100 shares of ISRG near today’s price of $401.23.
• Sell one call option on ISRG expiring 6/17/2027, with a strike price of $460, about 15% above today.
• Collect roughly $4,130 in premium up front per contract (each contract covers 100 shares), which you keep no matter what the stock does.
• That premium is about 12.2% annualized on the $40,123 of stock, income you earn just for holding.
• If ISRG finishes above $460, your shares are called away at $460. Counting the premium, your total return works out to about 30% annualized, but you give up any gains above the strike.

Called Away Or Not, You Pocket The Premium

If ISRG finishes below $460 on 6/17/2027, the call expires worthless, and you keep the full $4,130 premium and all your shares. That is about 10% over 310 days, income earned just for holding, and you are free to sell another call.

If ISRG finishes above $460, your 100 shares are called away at $460. You still keep the $4,130 premium, and counting it your total gain works out to about 25% over the holding period (about 30% annualized), a healthy exit. The cost of the trade is that any gain above $460 is no longer yours. And if the stock instead falls, you keep the premium but still ride the shares down, cushioned by that 10% payout.

What Upside Would You Be Handing Over?

The trade has one real cost: it caps your upside. So the decision boils down to this: how much blue sky are you really giving up? The bull case, and the reason you might regret capping your gains, is the powerful new product cycle. Hospitals are snapping up the new da Vinci 5 system, driving total placements up 18% year-over-year, with a 24% jump in the critical U.S. market. That kind of capital spending suggests customers are betting on future growth, which could easily pull the stock higher. Add in solid 20% procedure growth outside the U.S., and you have a clear path for a rebound.

But there’s a genuine counterargument, and it’s why getting paid to define your exit price could be the shrewder move. U.S. procedure growth has moderated to 12%, a slowdown management blames on temporary patient insurance issues. Some analysts, however, are asking if this is simply the “market maturing.” If the company’s core engine is slowing structurally, the stock’s valuation could be a heavy weight. We recently took a deeper look at the company’s premium valuation in a separate piece. This uncertainty makes the immediate, guaranteed income from selling a call look awfully tempting.

Ultimately, this trade is a bet on whether the new da Vinci 5’s momentum can reignite the whole story. If you’d be happy to sell your shares at a gain from here, collecting a cash payment now for that commitment is a strong proposition. The one number to watch is the next update on U.S. da Vinci procedure growth; its direction will likely settle the debate.

Find The Covered-Call Income On Your Holdings

You may not own ISRG, but you almost certainly own something that could be paying you. Our Covered Call Finder lets you type in a stock, or a few, and instantly see the income a covered call could generate on each, then dial the strike up or down with a slider to balance more income against more upside. It is the quickest way to see what the names in your own portfolio could pay.

One step out from a single name: a healthcare ETF like XLV owns the whole healthcare group at once, so no single company can sink you. It still rises and falls with that one theme, which is exactly the gap the portfolio below closes.

Pair The Premium With Real Diversification

Selling calls on a stock you own is a sensible way to manufacture income. It is still, by design, a concentrated position, and even owning a whole sector only trades single-name risk for single-theme risk. Real diversification means spreading across sectors, so one industry stumbling does not define your result.

The Trefis High Quality (HQ) Portfolio handles that: about 30 quality, cash-generative companies across sectors, chosen on the full weight of their fundamentals rather than one premium-rich setup, then sized and re-balanced with care. The payoff is a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Keep the income from trades like this, without pinning your future to any single name or theme.